Neurelis, Inc. v. Aquestive Therapeutics, Inc., Nos. D077984, D078186, 2021 Cal. App. LEXIS 965 (Ct. App. Nov. 17, 2021)
This suit by one drug company against its competitor for the latter's attempts to derail FDA approval of the plaintiff's drug gave rise to an Anti-SLAPP motion. The decision holds that the defendant's citizen's petition with the FDA seeking to prevent FDA approval of plaintiff's drug was protected activity under CCP 425.16(e) and that the Noerr-Pennington doctrine shielded defendant from… Read More